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Abstract
Evidence is now overwhelming that inflammation is a central process in the pathogen‐
esis of progressive Parkinson's disease (PD). The hallmark of this neuroinflammation is
the activation of microglial cells and the secondary role of adaptive immunity in both
the familial and idiopathic forms of PD, leading to the loss of dopamine‐producing cells
within the Substantia nigra. This activation is characterized by the oxidative stress
response, production of inflammatory mediators, recruitment and activation of immune
effector  cells  which  create  a  toxic  environment  for  dopaminergic  neurons,  and in
forming a continuous cycle of inflammatory responses that result in chronic neuroin‐
flammation and progressive neurodegeneration. This chapter focuses on the different
components of the inflammatory response that are involved in Dopamine‐neurodegen‐
eration,  the  evidence  for  inflammation  in  different  forms  of  PD,  and  the  role  of
inflammation in the various animal models of PD. Finally, we provide current evidence
that targeting this inflammation with a number of anti‐inflammatory therapies can be
an effective way to halt the progression of chronic neuroinflammation‐induced PD.
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1. Introduction
Recently accumulated evidence suggests that neuroinflammation and chronic inflammation of
the central nervous system (CNS) may play a critical role in the development of a number of
neurodegenerative diseases. Particularly, in Parkinson's disease (PD), neuroinflammation has
been proposed as a major contributing factor that plays a role in the initiation and progres‐
sion of the dopaminergic neuronal loss that is the hallmark of the disease. Evidence to sup‐
port neuroinflammation as the mode of pathogenesis for PD originates from postmortem studies
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in patients and animal models. The proliferation and activation of microglial cells, as well as
increased  levels  of  pro‐inflammatory  mediators  such  as  tumor  necrosis  factor  (TNF)‐α,
interleukin (IL)‐6, IL‐1β, nitric oxide (NO), and reactive oxygen species (ROS), are present in
postmortem analysis of brains and in the cerebrospinal fluid (CSF) of PD patients [1]. These
findings suggest that pro‐inflammatory cytokines, specifically TNF‐α, may be involved in
neuronal cell death. Likewise, neuronal cell death can release mediators that activate micro‐
glial cells— thereby potentiating a vicious cyclical inflammatory‐mediated neuronal cell death.
PD is unique in that the clinical symptoms appear after a loss of approximately 70–80% of striatal
nerve terminals and 50–60% of dopaminergic cells in the Substantia nigra pars compacta (SNpc),
the region of the brain that is responsible for controlling movement [2, 3]. This recent scientif‐
ic understanding is vital to developing potential early biomarkers and/or therapeutic strat‐
egies to help with better diagnosis and disease management. We discuss various components
of neuroinflammation, focusing on the role of the innate and adaptive immune responses as
they relate to PD. In addition, we briefly summarize the inflammatory pathology seen in the
genetic and toxin‐induced models of this disease, as well as discuss several anti‐inflammatory
therapies currently being used or tested as potential treatments for PD.
2. Innate immune response and PD
The innate immune response serves as the first line of defense to both infiltrating pathogens
and/or endogenous insults. As such, it primarily functions to initiate an immediate and
nonspecific response to any compound it deems unnecessary and/or a potential threat.
Pathogen‐associated molecular patterns (PAMPS) and/or endogenous damage‐associated
molecular patterns (DAMPs) can trigger an innate immune response. In the case of CNS, the
innate immune system has several components: cells that mediate an immune response, such
as microglia and astroglia, the complement system, and the physical obstruction imparted by
the blood‐brain barrier (BBB). For centuries, the CNS was thought to be immune privileged
because the BBB did not allow various compounds to enter the CNS through the circulatory
system. However, as we are beginning to appreciate the intricacy of the immune‐nervous
system interaction, the notion of immune privilege no longer holds [4].
In PD, the various components of the innate immune system are activated and the integrity of
the BBB is compromised, allowing for the innate‐mediated recruitment and activation of the
adaptive arm of the immune system. While PD is not among other immune‐dependent
degenerative diseases, Parkinsonian symptoms have been shown to develop after infectious
inflammatory diseases such as Epstein‐Barr virus (EBV)‐induced encephalitis. Likewise, many
anti‐inflammatory therapeutic agents have served protective functions in PD models [5]. As
such, while the role of the immune system is not clear and/or extensively studied in the etiology
of the disease, it is well established that the immune system is critical for the progression of
the disease. Initial activation of the innate immune cells as well as the complement proteins
may serve protective roles, but when these innate defense mechanisms become unregulated
and maladaptive, it leads to disease progression. As immediate responders, cells of the innate
immune system play an important role in initiating an inflammatory response against various
nonspecific components of endogenous DAMPS and/or PAMPs. The innate cells, astrocytes
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and microglia, play an active role in the pathological mechanism responsible for the progres‐
sion of the disease.
2.1. Astrocytes
Astrocytes make up about 20–40% of the glial cell population in the CNS. Their functions
include, but are not limited to, maintaining the integrity of the BBB, facilitating repair and scar
formation, and maintaining the extracellular ion homeostasis. The expression of receptors that
are critical for innate immunity such as Toll‐like receptors (TLRs), nucleotide‐binding
oligomerization domains, double‐stranded RNA‐dependent protein kinase, scavenger
receptors, mannose‐binding lectin receptor, and complement system components has
implicated a role for astrocytes in innate immunity [6]. The role of astrocytes in PD is debata‐
ble and not well understood. Studies are inconclusive as to whether astrocytes have a
neuroprotective effect and/or a neurotoxic effect in PD. However, astrocytosis, the activation
of astrocytes, has been reported in some cases of PD as demonstrated by an increase in the glial
fibrillary acid proteins (GFAP) [7, 8]. GFAP is an intermediate filament needed by astrocytes
to synthesize cytoskeletal structures and is a well‐established biomarker for astrocytosis [8].
Furthermore, activated astrocytes are reported in postmortem brains of PD patients; howev‐
er, this activation is not confined to the SNpc and its function therefore still remains elusive [9].
In contrast, astrocyte activation is not only well documented in the 1‐methyl‐4‐phenyl‐1,2,3,6‐
tetrahydropyridine (MPTP) and 6‐hydroxydopamine (6‐OHDA) models of PD, but it has been
reported to precede neuronal cell death [10–12]. In the MPTP model, astrocytosis and
dopaminergic cell death are synchronized. In the 6‐OHDA model, several laboratories
demonstrate that astrocytosis occurs in a time‐dependent manner, peaking at 4 days post
injection and remaining in the brain for about a month. There are also studies that contradict
the presence of astrocytosis post 6‐OHDA injection [13]. Therefore, while astrocytes are an
important cell type in the CNS, their role in inflammation and PD is not yet well established.
2.2. Microglia
In contrast to astrocytes, consistent microglial activation and the accompanying inflammato‐
ry response have been reported in both patient and animal models of PD. As the resident CNS
macrophage, microglia cells are responsible for scavenging the CNS milieu for potential
infiltrating pathogens and/or endogenous insults. Consequently, the phagocytic, cytotoxic,
and antigen‐presenting capabilities of these cells enable them to protect the CNS from various
insults. Activated microglia targets infiltrating pathogens and damaged cells by releasing toxic
ROS, free radicals, and phagocytosis. Evidence of microglial activation and its role in PD
pathogenesis is indisputable. Knott et al. [9] and others [14] have reported activated amoe‐
boid‐shaped microglia in postmortem brain of PD patients. These activated microglia cells are
densely located and confined to the SNpc with a limited presence in the vasculature of the
caudate and putamen regions. Additionally, in determining the role of microglia in PD
pathogenesis, our results as well as those from other groups [15–17] have shown that in various
PD models, microglial cells are needed for the pathogenesis of PD. For example, we have
shown that high doses of the β2‐adrenergic receptor agonist salmeterol can induce dopami‐
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nergic cell toxicity. However, microglial cells are indispensable in the β2‐AR‐mediated toxicity,
as high‐dose salmeterol has no effect on neuron‐only cultures [15]. In PD, the expression of
ROS, free radicals, and the enzymes responsible for the production of these species such as
NADPH oxidase (NOX or PHOX), induced nitric oxide synthase (iNOS), and myeloperoxi‐
dase (MPO) are elevated in the SNpc. These reactive species can activate microglial cells, and
these activated microglia release pro‐inflammatory cytokines TNF‐α, IL‐1β, and IL‐6 to recruit
additional lymphocytes in the process of inflammation. Additionally, these cytokines can
cause cytotoxicity in a direct, receptor‐mediated manner, and/or in an indirect manner by
inducing the further production of ROS and pro‐inflammatory cytokines [18]. For example,
dopaminergic cells express receptors for TNF‐α, which, upon binding the TNF‐α ligand, can
cause cell death through Fas ligand‐mediated apoptosis, and Tumor Necrosis Factor
Receptor (TNFR) knockout is protective in the MPTP model of PD [19]. Indirectly, TNF‐α can
also activate additional microglia to release ROS and a variety of pro‐inflammatory cyto‐
kines. This leads to a cyclical pathway whereby activation of a few cells can amplify the initial
insult to a greater magnitude. This process has been termed reactive microgliosis and is now
a leading working model for understanding and targeting neuroinflammation in PD [20].
3. Adaptive immune response and PD
Adaptive immune response is a highly specific response to injurious agents mediated by B‐
and T‐lymphocytes, which is characterized by the humoral and cell‐mediated response,
respectively. These cells are activated by specific antigens and directly induce toxicity and cell
death to the antigen‐expressing cell. It is important to note that the adaptive immune cells
require an antigen‐presenting cell to prime the B‐ and/or T‐cell to recognize a specific antigen.
In PD, innate immune activation leads to an increased BBB permeability, allowing for the
infiltration of peripheral T‐cells and B‐cells [21]. These infiltrating cells are activated by active
microglia expressing MHC 1/II through presentation of endocytosed peptides to the respec‐
tive cells. Evidence to suggest the involvement of adaptive immune system is that single‐
nucleotide polymorphism (SNP) in the MHC Class II predisposes individuals to PD, implying
the role of both the innate and adaptive immune response in PD pathogenesis. Recent genome‐
wide association studies (GWAS) have highlighted alleles HLA‐DRA (for Class I) and HLA‐
DRB5 (for Class II) as risk factors for PD [22]. Furthermore, MHC Class I proteins are typically
used by CD8 T‐cells and require β2‐microglublin, a protein required for the structural stability
of MHC Class I, and in PD, the expression of β2‐microglublin is found to be increased on
microglial cells [21]. Additionally, an increase in the number of cytotoxic CD8 and CD4 T‐cells
infiltrating into the SNpc of PD patients is accompanied by a decrease in the cytotoxicity‐
suppressing capacity of regulatory T‐cells (Treg) [23, 24]. Therefore, it suggests that toxicity of
these effector T‐cells is not properly regulated and can exacerbate neuronal cell death in the
SN. With regard to B‐cells, antibodies (Ab) to dopaminergic neurons have been found in the
CSF of a proportion of the PD patients, thus implicating the involvement of the peripheral
humoral arm of the adaptive immune response [25, 26]. Furthermore, immunization, which
uses B‐cells to generate antibodies against an antigen, with bovine mesencephalic homoge‐
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nates [27] and hybrid dopaminergic cell line homogenates [25], can cause selective DA neuron
damage in a microglia‐dependent manner. The adaptive immune system has a delayed
contribution to the pathology of PD but, nevertheless, is important to understand in order to
develop therapies that can mitigate and counter the pathology induced by this system.
4. Neuroinflammation and overlapping vulnerability of Substantia nigra
(SN) neurons
The oxidative stress hypothesis focuses on the role that reactive oxygen and nitrogen species
play in the neurodegeneration seen in PD. Reviews by Fahn and Cohen [28] as well as by
Zigmond and Burke [29] discuss four characteristics of SNpc dopaminergic neurons that
support the oxidative stress hypothesis as one of the major mechanisms responsible for the
pathology of PD. However, understanding these characteristics can help explain the chronic,
self‐perpetuating inflammatory pathology that is responsible for disease progression in PD.
While inflammation involves activated immune cells and the release of a multitude of pro‐
inflammatory cytokines, the cycle does require a start point. The etiology of PD is unknown
as is what gives rise to the chronic inflammatory pathogenesis seen in PD. Two different
explanations of the chronic etiology of PD suggest that neuronal cell death leading to activated
immune cells and the resulting uncontrolled inflammation further exacerbates cell death, or
that activated immune cells cause cell death which results in the activation of additional
immune cells resulting in a vicious cycle of immune cell‐mediated inflammation and neuro‐
nal death. The characteristics of SNpc dopaminergic cells make them vulnerable to ROS,
subsets of which are important pro‐inflammatory cytokines. First, dopamine degradation
occurs by oxidative deamination, resulting in the production of H2O2 that then react with iron
present in the neurons to form reactive radicals. Second, superoxides and free radicals are by‐
products of the reaction between dopamine and the readily available oxygen to form reac‐
tive quinones. Third, the SNpc particularly rich in iron and hence the neurons found therein
are more vulnerable to cell death via oxidative stress. Fourth, the SNpc neurons contain
neuromelanin, which is formed by the auto‐oxidation of DA, and the by‐product of this
reaction is ROS. These characteristics make SNpc neurons particularly sensitive to a cyclical
process of oxidative stress contributing to inflammation that that leads to furthermore
neuronal damage.
5. Genetic causes of PD and neuroinflammation
Although PD is typically a sporadic disease, approximately 10% of PD cases have been linked
to several specific genes. These genes are α‐synuclein, Parkin, UCH‐L1 (ubiquitin C‐terminal
hydrolase L1), PINK1 (PTEN‐induced kinase 1, NB for mitochondrial function), DJ‐1, LRRK2
(leucine rich repeat kinase2), Pael‐R, and glucocerebrosidase [21, 30, 31]. These genes and their
products have a role in the degradation of α‐synuclein and/or in the control of the oxidative
milieu. Mutations in genes encoding α‐synuclein, Parkin, and/or UCH‐L1 result in the
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accumulation of misfolded α‐synuclein protein and are accompanied by neuronal cell death
[21]. Additionally, a pathological feature of PD is the Lewy body cytoplasmic inclusion bodies,
which primarily consist of α‐synuclein, tau, ubiquitin, and Parkin. These genes were identi‐
fied in familial PD, as risk factors for sporadic PD, and further verified by a GWAS. There‐
fore, understanding the role of these genes and their products in mediating inflammation can
help not only in developing more holistic model(s) of PD but also for therapy development.
5.1. LRRK2
Leucine‐rich repeat kinase 2 (LRRK2) is an enzyme that is commonly expressed on multiple
immune cells such as B‐cells, monocytes, dendritic cells, and microglia [32]. Mutations in
LRRK2 are associated with autosomal dominant form of PD with high resemblance to the
idiopathic PD phenotype and other inflammatory‐mediated diseases as Crohn's disease [33]
with a high predisposition to leprosy infection [34]. LRRK2 is a member of the receptor‐
interacting protein kinase (RIPK) family. The RIPK family has important roles in immunity as
well as regulating of cell death [35]. Furthermore, TLRs are an important activator of micro‐
glial cells. In the TLR‐signaling pathway, LRRK2 is phosphorylated [36], and Kim et al. [37] as
well as other groups [38] have reported a decrease in NF‐κB‐mediated transcription, specifi‐
cally of TNF‐α, post LRRK2 phosphorylation. NF‐κB is a major transcription factor for many
of the pro‐inflammatory cytokines that are reported to play a role in the pathogenesis of PD,
such as TNF‐α, IL‐1β, and IL‐6; LRRK2 modulation of NF‐κB will have important cellular
effects on the inflammatory state of the activated microglial cells. Furthermore, a mutation in
LRRK2, specifically R1442G, is reported to alter the phenotype of activated microglial cells to
produce higher amounts of inflammatory cytokines with a decrease in the production of anti‐
inflammatory cytokines [39]. Gillardon et al. [39] tested the neurotoxicity of these microglial
cells on cortical neurons by exposing neurons to conditioned medium from LPS‐activated
microglial cells, compared to conditioned medium from LPS‐activated wild‐type (WT)
microglia, conditioned media from LPS‐activated LRRK2 mutant significantly increased cell
death. In addition, Kim et al. [37] have shown that LRRK2 deficiency mitigates LPS‐mediat‐
ed increase in the mRNA of iNOS, TNF‐α, IL‐1β, and IL‐6. By itself, overexpression of the
mutant LRRK2 in vivo and in vitro causes neurotoxicity [40]. These data support a role for
LRRK2 in regulating the inflammatory response of microglial cells and the resulting effect on
neuronal viability.
5.2. Parkin
Parkin is an important component of the multi‐protein E3 ubiquitin ligase complex that is
responsible for the ubiquitin‐proteasome‐mediated degradation of α‐synuclein in the brain.
Mutations resulting in loss of function of Parkin are responsible for autosomal recessive form
of juvenile PD [41]. Parkin not only regulates mitochondrial health but also is involved in the
regulation of the NF‐κB signaling pathway [42]. Parkin ubiquitinates damaged mitochon‐
dria and subjects it to mitophagy and clearance from the cell [43]. Similarly, activated Parkin
catalyzes ubiquitination of the IkB kinase (IKK) subunit IKKγ, resulting in the downstream
activation of NF‐κB [42, 44]. In this NF‐κB signaling pathway, TNF‐receptor‐associated
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factor‐6 (TRAF6) also plays a role in regulating IKK activity. Loss‐of‐function mutation in
Parkin increases the expression of TRAF6 [45], thereby activating transforming growth
factor‐1 (TAK1) that activates IKK and ultimately NF‐κB and its associated transcriptional
activity [44]. With regard to Parkin and mitochondria, while mitophagy and PD have not yet
been linked, damaged mitochondria are a source of ROS that can activate microglial cells
through TLR‐PAMP/DAMP pathways [30].
5.3. α‐Synuclein
α‐synuclein is an 18‐kDa protein found in high concentrations in the CNS compared to other
areas. While the function of α‐synuclein is unclear, it is thought to be important for the release
of neurotransmitters and vesicle trafficking [46, 47]. Mutations in the SCNA, gene coding for
α‐synuclein, is implicated in inherited forms of PD. Similarly, α‐synuclein aggregation is a
critical component of Lewy bodies in both sporadic and genetic PD. With regards to inflam‐
mation, α‐synuclein is thought to activate microglial cells through the nonspecific DAMP‐
TLR2/4 pathway [48,49]. An emerging link between gut microbiota and peripheral
inflammation and PD is of interest to note. A study by Forsyth and colleagues [50] reported
increased gut permeability and Escherichia coli (E. coli), a Gram negative bacterium, staining in
early onset PD patients. The implication of this study is that E. coli‐dependent inflammatory
processes resulted in an increased iNOS that then nitrosylated α‐synuclein. WT, mutant,
aggregated forms of α‐synuclein can all trigger microglial activation by acting as a TLR‐ligand.
Conditioned media from dopaminergic cell line SH‐SY5Y that either overexpressed WT or
A53T mutant α‐synuclein activated BV‐2 microglial cell line, with the conditioned media from
the neurons overexpressing mutant α‐synuclein caused a more robust increase in TNF‐α, IL‐
1α, and IL‐1β [51]. More importantly, mutant and aggregated fibrils of α‐synuclein are
reported to have cell‐to‐cell transmission capacity, thereby causing neuronal toxicity in a prion‐
like mechanism as well [52]. Moreover, nitrated α‐synuclein can activate peripheral immune
activation, especially T‐cells and initiate the involvement of the adaptive immune response.
Lastly, Tran and colleagues [53] have recently reported that antibodies to α‐synuclein can offer
a promising protective effect by inhibiting the entry of α‐synuclein fibrils into neurons and
causing neuronal death.
5.4. PINK1
PINK1 is a mitochondrial serine/threonine protein kinase implicated in providing cellular
protection against mitochondrial‐associated oxidative stress. As such, it is reported to regulate
stressed mitochondria by enabling the binding of Parkin to stressed mitochondria and
inducing autophagy. The role of PINK1 in inflammation is somewhat unclear; as evidence
suggests that in PINK1 null animals injected with LPS, IL‐1β, IL‐12, and TNF‐α are in‐
creased [54]. However, in PINK1‐deficient embryonic fibroblasts, there is no increase in pro‐
inflammatory cytokine production post LPS injection because of decreased NF‐κB activity [54,
55]. As such, experiments aimed at understanding the role of PINK1 in inflammation should
be investigated in microglial cells which are known to propagate the inflammatory response
in PD.




DJ‐1, or Parkinson's disease Protein 7, inhibits the aggregation of α‐synuclein, thereby acting
as an oxidative stress sensor. PINK1 and DJ‐1 deletion causes disruption of other genes
involved in mitogen‐associated protein kinase (MAPK)/NF‐κB signaling pathway and thereby
alters the innate immune response of the microglia and other inflammatory cascades [6].
MAPKs are signaling proteins that mediate various intracellular signals in response to external
stimuli. Several important MAPKs play an essential role in the integrity of the cell as well as
modulating inflammation such as p38, C‐Jun N‐terminal kinase (JNK), and extracellular signal‐
regulated kinases (ERKs). In astrocytes, DJ‐1 loss of function primes astrocyte to release
increased pro‐inflammatory cytokines post LPS challenge [56]. This response was mediated
through p38 and JNK, thereby DJ‐1 may have a pivotal role in regulating TLR4‐MAPK
signaling and downstream transcriptional responses [57]. LPS‐mediated activation of
macrophages increases DJ‐1 expression [58], which is aligned with the associated TLR/MAPK‐
mediated signaling in microglial cells challenged with LPS.
6. Inflammation and PD models
There are several models of PD, both toxin based and gene based, used to study disease
progression and/or therapeutic development. In many of these models, inflammatory
mechanisms are reported to play roles in the pathogenesis and manifestation of the disease in
various animal models. In the remainder of this chapter, we will focus on characterizing the
inflammatory response seen in the various models.
6.1 Toxin‐based models
6.1.1. MPTP
1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) is a dopaminergic neurotoxin selec‐
tive for the dopaminergic cells of the SNpc. It is a lipophilic compound capable of crossing the
BBB, and once it has crossed the BBB, it is oxidized to MPP+ by MAO‐B. MPP+ interrupts the
mitochondrial complex I of the electron transport chain (ETC) and results in cell death and
release of ROS [23]. The MPTP model is a widely used model to develop animal models of the
disease, as PD progression post MPTP administration is similar in both humans and mon‐
keys [59]. In the MPTP model, microglial activation accompanied with an increased endothe‐
lial expression of adhesion molecules on the BBB to enable infiltration of T‐cells is reported
[21]. Additionally, there are an increased number of activated microglial cells which are
amoeboid in shape representative of activated cells [23]. Astroglial cells are activated late in
the disease, and their role is unclear. Infiltrated CD8 and CD4 T‐cells have lymphocyte
function‐associated antigen‐1 (LFA‐1), a protein expressed for recruitment and these infiltrat‐
ed T‐cells are primarily located it the SNpc and striatum. Furthermore, an increased expres‐
sion of MHC I and MHC II and microglial iNOS expression are observed [23]. In conjunction
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with anti‐inflammatory therapies, minocycline, a potent inhibitor of microglial activation and
iNOS knockout mice, is protective against MPTP‐induced neuronal cell death.
6.1.2. 6‐OHDA
Oxidopamine, commonly known as 6‐hydroxydopamine (6‐OHDA), is another dopaminer‐
gic neurotoxin capable of inducing PD symptomatology in animal models. In the 6‐OHDA
model, inflammatory pathology is propagated by activated microglial cells which occurs 1–3
days post intranigral injection of 6‐OHDA and DA neuronal loss occurring 1 week post
injection [23]. As part of the inflammatory milieu, there is an increase in TNF‐α, a pro‐
inflammatory cytokine capable of inducing cell death through TNFR.
6.1.3. LPS/rotenone
Lipopolysaccharide (LPS) is an endotoxin derived from Gram negative bacteria and another
widely used toxin to induce PD in animal models. The LPS model is different from MPTP and
the 6‐OHDA toxin‐based models, as LPS will activate microglial cells through the TLR2/4
receptors. Activated microglial will upregulate NO, superoxide, TNF‐α, and IL‐1β produc‐
tion and release [60]. These pro‐inflammatory mediators can cause neuronal cell death. In
animal models, intranigral injection of LPS induces microglial activation prior to neuronal
loss [32]. Rotenone is another lipophilic herbicide that disrupts the mitochondrial complex 1
causing cell death and associated upregulation in ROS. In the rotenone animal models of PD,
fibrillary cytoplasmic inclusions equivalent of Lewy bodies is found in the SNpc. In addition,
rotenone injection in neuronal‐only culture does not cause DA cell death, but in a mixed
neuronal‐microglial culture, DA neuron cell death is observed. This suggests that rotenone
requires microglial cells for its toxicity [23, 61]. Lastly, inhibition of superoxide is protective
against rotenone‐induced DA neuron degeneration. These two models suggest that while the
etiology of disease is unknown, microglial cells are indispensable for the progression of disease
and the resulting neuronal degeneration is seen in PD.
6.2. Gene‐based models
6.2.1. α‐synuclein
Genetic model of PD is very rare and not all as consistent and reproducible as the toxin‐based
models. While many genes are implicated in the PD etiology, α‐synuclein is the most widely
used gene‐based model so far [62]. The α‐synuclein models include a transgenic knockout and
overexpression of mutant or WT α‐synuclein [63]. Viral vectors expressing human α‐synu‐
clein injected into adult brains have also been used to increase α‐synuclein in the respective
brain regions. α‐synuclein models have been developed in monkeys, rats, mice, and in flies.
Bae et al. [63] as well as Watson et al. [64] reported astroglia and microglia activation accom‐
panied with increased mRNA transcripts of TNF‐α and several TLRs (1, 4, and 8) in SNpc [65].
α‐synuclein can act as a DAMP and activate microglia via TRLs, thereby suggesting a primed
microglial sensitivity. In the knockout transgenic models of α‐synuclein, little neuronal loss
and behavioral changes are reported. In addition, transgenic null mice can offer a degree of
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protection against MPTP intoxication and cell death [66, 67]. In contrast, viral overexpres‐
sion models of α‐synuclein in brain of adult animals show DA neurotoxicity accompanied by
the activation of both the innate and adaptive immune response [68]. Learning from these
models includes and further verifies a gain of function of α‐synuclein as ablation of α‐synuclein
features no neuropathological changes [62]. Furthermore, in a recent study, Van der Perren et
al. [69] reported the immunophilin ligand FK506 in a rAAV2/7 α‐synuclein overexpression rat
model to have anti‐inflammatory therapeutic potential. Specifically, the group [69] reported a
decrease in the infiltration of CD4+ and CD8+ T cells as well as in the number of activated
microglial cells. This further supports neuroinflammation as a key to the progression of the
disease and efficacy for therapeutic development.
6.2.2. LRRK2
LRRK2 mutations are implicated in an autosomal dominant form of PD with similar pheno‐
typic expression as idiopathic PD. To study the role of LRRK2 in PD pathogenesis, LRRK2
knockout animals were developed. Several groups [70,71] report no DA degeneration in
LRRK2 deficient rat and mice models. Lee et al. [72] developed herpes simplex virus (HSV)
amplicon‐based mouse model of LRRK2 dopaminergic neurotoxicity. Overexpression of the
LRRK2 G2019S resulted in significant loss of tyrosine hydroxylase (TH+) neurons. Thereby
these data suggest that knockout of LRRK2 may provide neuroprotection, and similarly, Lee
et al. [72] used LRRK2 inhibitors and found that it protected the overexpressed LRRK2 mice
from developing PD [72]. Most notably, the mechanism of protection seems to be dependent
on the activation and proliferation of microglial cells [70], implicating LRRK2 in the inflam‐
matory etiology for PD. Therefore, it appears LRRK2 is critical in PD pathology and plays a
significant role in regulating cellular inflammation, thereby supporting the notion that
neuroinflammation is critical to PD pathogenesis.
7. Anti‐inflammatory therapies in PD
While evidence strongly suggests that inflammation plays a major role in the etiology of a
number of different forms of PD, emerging evidence also demonstrates that therapies used to
lessen inflammation, including those directed against immune cells or inflammatory media‐
tors, can play a positive role in halting the degeneration of DA neurons in several models of
PD. Many studies suggest that inflammatory mediators such as TNFα, PGE2, NO, free radicals,
and other immune mediators play a role in the pathogenesis of PD and degeneration of
dopamine‐producing neurons, and that the use of specific reagents that target these media‐
tors, inhibition of cellular signaling mechanisms that regulate the production of these
mediators, or the use of neurotrophic factors that help protect against the neurotoxicity
induced by these mediators hold significant promise as therapeutic treatments for PD. In
addition, epidemiological and observational studies already suggest that use of anti‐inflam‐
matory drugs lower the risk of developing PD [73].
Challenges in Parkinson's Disease66
Observations which demonstrate that inflammation in SNpc plays a role in PD led many
investigators to initially study the potential use of steroidal and nonsteroidal anti‐
inflammatory drugs for the treatment of PD. Steroidal anti‐inflammatory drugs (SAIDs) such
as dexamethasone showed neuroprotective effects and LPS‐induced neurotoxicity in
Substantia nigra [74]. Nonsteroidal anti‐inflammatory drugs (NSAIDs) are used as analgesics
and anti‐pyretics to suppress the adverse effects of inflammation. NSAIDs as a group normally
reduce the production of prostaglandins by inhibiting cyclooxygenase (COX, an enzyme that
catalyzes specific prostaglandin synthesis) and also reduce the synthesis of nitric oxide. In
addition, it has been found that a subset of NSAIDs called as selective Aβ42 lowering agents
(SALAs) reduces the risk of Alzheimer dementia (AD) [75] and consequently may be effective
in PD as well. Neuroprotective effects of ibuprofen have been studied in PD pathogenesis, and
these studies show that it can protect dopaminergic neurons against glutamate toxicity in vitro
[76, 77]. It is interesting to note that some neurologic drugs used to treat PD have been found
to result in changes to immune system. One such drug, amantadine (Symmetrel, Endo Pharmac
LPS induced mice and mesencephalic culture
6‐OHDA induced euticals) which functions as an antagonist of the NMDA‐type glutamate
receptor leading to increased dopamine release and dopamine reuptake, also increases the
CD4:CD8 ratio [78] and enhances IL‐2 levels in PD patients. In contrast, L‐DOPA monotherapy
does not show similar effects [79]. In the next sections, we discuss the effectiveness of a number
of anti‐inflammatory treatments in preventing dopaminergic cell death in animal models of
PD (section summarized in Table 1).
Therapy Compounds Study design Outcomes Reference
SAIDs and
NSAIDs
Dexamethasone  Intra‐nigral injection of LPS in
rats 
↑ TH activity in striatum.  [73] 
Ibuprofen  Primary mesencephalic








↑ CD3+ CD4+ cells, improves T‐cell
mediated immunity. 
[77] 
Antibiotics  Rifampicin  LPS induced BV2 microglia  ↓ in NFkB activation,
↓ expression of iNOS, COX2,
TNF‐α, IL‐1β
↓production of NO, PGE2. 
[81] 
MPP induced PC12 cells  ↓MPP induced neuronal death,
↓expression of α‐syn multimer. 
[83] 
Ceftriaxone  PC12 cells exposed to
neurotoxin 6‐OHDA 
Binds with α‐syn and blocks its
polymerization in vitro 
[85] 
6‐OHDA induced PD rat
model 
↑GLT‐1 expression, reduces striatal
TH loss. 
[86] 
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Therapy Compounds Study design Outcomes Reference
D‐cycloserine  MPTP induced PD rat
model 
Improved behavioral deficits
restored IL‐2 level ↓microglial
activation. 
[87] 
Rapamycin  In PC12 cells and MPTP
induced mouse model 
↓neuronal death, regulate Akt
phosphorylation at Thr308. 
[89] 
Minocycline  In MPTP induced mouse
model, primary
mesencephalic culture 






cells induced by reactive
oxygen species 
Specific scavenger of peroxynitrite,
↓microglia activation. 
[91] 
Neuropeptides  PACAP  MPP+ induced SHSY‐5Y
neuroblastoma 
↓cell death, ↑ cAMP  [98] 
Oxygen and glucose deprived
BV2 microglia 
↓TRL4, MyD88, NFkB ↓production
of pro‐inflammatory cytokines 
[95] 
MPTP induced mice  ↑TH expression, ↓caspase‐3, IL‐6,
TNF‐a 
[98] 
VIP  LPS induced mice and
mesencephalic culture
6‐OHDA induced 
↓pro‐inflammatory cytokine, ↓NO  [99] 
Polyphenols  Pinocembrin  6‐OHDA SHSY‐5Y  ↓apoptosis, ↓ROS  [101] 
Naringenin  6-OHDA induced mice and
SHSY-5Y 








Curcumin  6‐OHDA induced SHSY‐5Y  ↓p‐p38, ↓caspase‐3  [105] 
Baicalein  MPTP induced mice and
primary rat astrocytes 
↓NFkB nuclear translocation,
↓microglia and astrocyte activation,
↓COX2, ↓phosphorylation of JNK
and ERK 
[106] 
Theaflavin  MPTP with probenecid
induced mice 
↑TH expression, ↓caspase‐3,8,9,
↓COX2, IL‐1β, TNF‐α, IL‐6 
[109] 
Resveratrol  MPTP induced mice  ↑TH protein and mRNA, ↑SOCS‐1,
↓TNF‐α, IL‐1β,IL‐6, ↓TNF‐αR1, IL‐
1βR1, IL‐Rα 
[110] 
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Therapy Compounds Study design Outcomes Reference




↓NO, ROS, MPO, ↓iNOS, COX2,






IL‐10  LPS induced mesencephalic
culture 
↓TNF‐α, NO, ↓extracellular
superoxide, inhibit PHOX activity 
[112] 
Hu‐IL‐10 gene transfer in 6‐
OHDA induced rats. 
↑TH‐positive neurons, ↓ glial
activation 
[113] 
TGF‐β  Retrograde model of PD
induced with 6‐OHDA and
treated with TGF‐β alone and





LPS and MPTP induced
mice 
↓ROS, ↓PHOX p47phox activity,
↓LPS activated phosphorylation of
ERK and p47phox 
[116] 
Insulin therapy  Pioglitazone  MPTP induced mice  ↓microglial activation, ↓GFAP
positive cells in SN, ↑ IkBα, ↓NFkB
activation 
[121] 
LPS induced rat microglial
cells 















Salmeterol  LPS and MPTP induced
mice 











Sinomenine  LPS and MPP+ induced rat
mesencephalic culture 
↓TNF‐α, PGE2, ROS ↓PHOX
activity. 
[128] 
3‐HM  Rat mesencephalic culture
stimulated with LPS 
↓NO, TNF‐α, PGE2, ROS
↓microglia activation 
[129] 
LPS and MPTP models  ↑expression of neurotrophic





NBD  MPTP induced mice  ↓NFkB activation, ↓iNOS, ↓TNF‐α,
IL‐1β ↓CD11b, ↓neuronal death 
[132] 
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Therapy Compounds Study design Outcomes Reference
Compound A (IKK
inhibitor) 













↓neurotoxicity ↓NOX2 activation.  [135] 
LPS induced rats and
mesencephalic culture 
↓ROS, ↓TNF‐α, NO ↓ERK
phosphorylation, ↓PHOX activity 
[136] 
Coenzyme Q10  MPTP model  ↓ROS, ↓free radicals production,
↓neurotoxicity 
[137] 
NAC  Intravenous infusion of NAC
in PD patients MPP+ induced
PC12 cells 
↑glutathione level in blood  [140] 
Edaravone  ↓oxidative stress, ↓ROS ↑Heme‐
oxygenase‐1 expression 
[142] 
Table 1. Neuroprotective effects of anti‐inflammatory therapies.
7.1. Antibiotics in neuroprotection in PD
Antibiotics are routinely used to kill or inhibit the growth of microorganisms at low concen‐
trations. In addition to their antimicrobial activity, antibiotics can either directly or indirect‐
ly regulate the expression of many inflammatory gene transcripts [80], and a number of
antibiotics such as tetracycline and β‐lactams have been shown to have significant anti‐
inflammatory properties [81]. Antibiotics now appear to have protective effects against
neurodegeneration and the neuroinflammatory process [82]. These properties of antibiotics
make them suitable for the development of effective therapies against neurodegenerative
diseases such as PD. Rifampicin, a macrocyclic antibiotic, upregulates Ab clearance in brain,
and it is also neuroprotective in other chronic neurodegenerative diseases and cerebral
ischemia [83]. Pretreatment with Rifampicin increases cell viability and reduces α‐synuclein
expression and its aggregation. Moreover, in MPP+‐induced PC12 cells, Rifampicin prevents
the formation of α‐synuclein oligomer [84]. It can also block the release of pro‐inflammatory
cytokines such as NO, PGE2 TNF‐α, and IL‐1β from LPS‐stimulated BV‐2 microglial cells [85].
Similarly, β‐lactam also has protective role against neurodegeneration and can cross BBB. β‐
lactam antibiotic ceftriaxone has demonstrated neuroprotective activity as well as high binding
affinity with α‐synuclein and can block its in vitro polymerization [86]. Ceftriaxone also
increases the expression of glutamate transporter‐1 (GLT‐1) which enhances glutamate uptake
and therefore reduces excitotoxicity in 6‐OHDA model of PD [87]. D‐cycloserine (DCS), an
antibiotic prescribed for Mycobacterium tuberculosis, also acts as an NMDA receptor
antagonist that prevents excitotoxicity damage induced by MPTP [88] and inhibits the
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production of MMP3 and MMP9 in LPS stimulate microglial cells. In addition, Rapamycin was
able to prevent mitochondrial dysfunction in PINK1/Parkin Drosophila mutants [89].
Furthermore, it enhances the expression of neuronal survival promoting kinase Akt, antioxi‐
dant enzymes and anti‐apoptotic markers [90]. Similarly, Minocycline has shown neuropro‐
tective effects in PD models [91]. Minocycline suppresses α‐synuclein aggregation and its
toxicity [92], as well as microglial activation of p38 the MAPK signaling pathway resulting in
the suppression of pro‐inflammatory mediator release [93]. These results support the poten‐
tial of antibiotics as neuroprotective and therapeutic agents in PD.
7.2. The role of anti‐inflammatory compounds in neuroinflammation and PD
Neurotrophic factors are essential for neural growth and development, and these factors
normally signal through Trk receptors. Adenosine and pituitary adenylate cyclase‐activat‐
ing peptide (PACAP) act as ligands and induces activation of Trk receptors through adeno‐
sine (A2A) receptor and PAC1 receptors, respectively [94]. Recent studies reported the
antioxidant and anti‐inflammatory properties of PACAP [95, 96]. It can inhibit the release of
several pro‐inflammatory mediators from LPS‐activated microglial cells by inhibiting the
transcriptional activity of NF‐kB [97], as well as the production of several chemokines like
MIP‐1α, ‐1β, MCP‐1, and RANTES [98]. A synthetic analog of PACAP showed neuroprotec‐
tion in MPP+‐induced SHSY‐5Y cells and MPTP‐injected mice. It restored the expression of
tyrosine hydroxylase in Substantia nigra and modulated the inflammatory response [99].
Another peptide, called vasoactive intestinal peptide (VIP), can also inhibit the expression of
pro‐inflammatory cytokines from LPS‐activated cultured microglia [100]. These studies
suggest these peptides can serve as promising molecules for the development of anti‐inflam‐
matory and neuroprotective drugs in the treatment of PD.
7.2.1. Neuroprotective and anti‐inflammatory role of polyphenols
Several traditional medicinal plants and herbs are rich in polyphenol, and their neuroprotec‐
tive effects have been studied extensively. These compounds have neuroprotective proper‐
ties against oxidative stress, neuroinflammation, mitochondrial dysfunction, and protein
fibrillization. Kong et al. reported that polyphenols reduce the intracellular level of ROS in DA
neurons [101]. Recently, it has been found that pretreatment with flavonoids such as pino‐
cembrin [102] and naringenin [103] reduces the formation of ROS, in 6‐OHDA‐challenged
human neuroblastoma SHSY‐5Y cells. This effect was due to an increase in Nrf2 protein level
and by activating ARE pathway genes. In addition, flavonoids from Selaginella species have
the ability to increase the expression and activity of anti‐oxidative enzymes endogenously
[104], and the aqueous extract of Selaginella suppresses rotenone induced neurotoxicity,
attenuated locomotor dysfunction, oxidative stress, and mitochondrial dysfunction in
Drosophila melanogaster [105]. Polyphenols may also target MAPK pathways and apoptosis,
since phosphorylation of MAPK and expression of cleaved caspase 3 were reduced in 6‐OHDA
induced SHSY‐5Y cells by curcumin [106]. Similarly, the phosphorylation of NF‐kB, JNK, and
ERK was inhibited by flavone baicalein in MPP+‐induced primary astrocytes and indicated its
implication in the treatment of PD [107]. Several other polyphenols have been shown to reduce
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the expression of pro‐inflammatory cytokine such as IL‐1β, TNF‐α, and IL‐6 [108, 109].
Furthermore, theaflavin treatment in MPTP mice model of PD increases the expression of anti‐
inflammatory cytokines such as IL‐4 and IL‐10 by the modulation of the suppressor of cytokine
signaling 1 (SOCS1). Oral administration of resveratrol in MPTP mouse model upregulated
the expression of SOCS1 in striatum and Substantia nigra and suppresses the production of
pro‐inflammatory cytokines [110] and also improved cell survival in rotenone‐induced
primary mesencephalic culture. Resveratrol also diminished the level of MPO (MPO; an
enzyme produces hypochlorous acid and tyrosyl radical during microglial respiratory burst)
and ROS in MPP+‐induced BV2 microglia cells [111, 112]. Many polyphenol compounds have
been studied to test their neuroprotective and anti‐inflammatory properties, but further
research will be needed to understand the signaling mechanism of how these compounds act
to offset neuroinflammation.
7.2.2. Anti‐inflammatory cytokine therapies in PD
The use of anti‐inflammatory cytokine serves as a potent approach for the development of anti‐
parkinsonian drugs. Two major anti‐inflammatory cytokines, IL‐10 and transforming growth
factor beta 1 (TGFβ1), produced by Treg cells, have been studied in PD models. Pre‐ and
posttreatment of rat mesencephalic neuron glia culture with IL‐10 showed neuroprotective
effects against LPS‐induced neurotoxicity by inhibiting the production of TNF‐α, nitric oxide,
and extracellular superoxide [113]. Gene delivery of human IL‐10 by using adeno‐associated
viral type‐2 (AAV2) in 6‐OHDA rat model of PD also showed neuroprotection by suppress‐
ing the 6‐OHDA‐induced loss of TH‐positive neurons [114]. Similarly, TGFβ1 also shows
protective effects against neurotoxicity. TGFβ1 in combination with GDNF reduces progres‐
sive cell death and enhances the expression of TH in surviving nigral neurons in retrograde
model of Parkinsonism in rats [115]. It has also been shown that TGFβ1 protects from neuronal
death induced by glutamate excitotoxicity [116]. The neuroprotective effect of TGFβ1 is
primarily due to its ability to inhibit the production of ROS from microglia during activation.
Additionally, after LPS activation, ERK phosphorylation and subsequent serine phosphory‐
lation on p47phox were significantly inhibited by pretreatment with TGFβ1 [117]. Recently, it
also has been reported that overexpression of fractalkine (CX3CL1) reduces neuronal loss in
6‐OHDA model of PD and suppresses α‐synuclein‐mediated neurodegeneration [118]. The
use of these anti‐inflammatory mediators therapeutically to suppress represents a new
therapeutic avenue for the treatment of PD.
7.2.3. Regulatory T‐cell therapy
Treg cells have the capability to mitigate inflammation and serve as an attractive therapeutic
target. Treg cell therapy can be used for neuroprotection in PD as these cells also utilize
immunosuppressive mechanisms including the production of anti‐inflammatory cytokines.
The neuroprotective effects of bee venom is associated with the deactivation of microglia and
suppression of CD4+ T cell infiltration, and it also increases the proportion of CD4+, CD25+ and
Foxp3+ Treg cells in MPTP mouse model of PD. Several studies have been shown that Treg cell
responses inhibit microglial activation and enhance neuronal survival in MPTP mouse model
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of PD [24, 119]. In addition, another type of Treg cell, Th2 cells also inhibit microglial activa‐
tion by the production of IL‐4 and IL‐10 against MPTP‐induced neurotoxicity. What signals
suppress the Treg cell functions and how to improve anti‐inflammatory activity are yet to be
determined.
7.2.4. Insulin as potent therapeutic agent for treatment in PD
Insulin is the enzyme most responsible for lowering the blood glucose, but it has also been
found to have potent anti‐inflammatory effects. Insulin signaling regulates a number of cellular
processes such as neurotransmission, vesicle trafficking cell survival, and inflammatory
mediator production. Recent evidence has shown that insulin signaling is impaired in
Alzheimer and, to some degree to, Parkinson's patients. Preclinical studies suggest that the
application of insulin or long‐lasting analogs of incretin peptides in transgenic animal model
of PD, and AD reduces neurodegeneration and neuronal and synaptic functionality [120, 121].
Pioglitazone is generally prescribed for type 2 diabetes mellitus and reduces insulin resist‐
ance and acts on peroxisome proliferator‐activated receptor γ (PPARγ) receptors. It also
functions to reduce microglial activation and induction of iNOS positive cells by enhancing
inhibitory protein kappa B (IkBα) and inhibition of NF‐kB subunit p65 in MPTP mouse model
of PD [122]. In LPS model of PD, Pioglitazone showed neuroprotection by inhibiting micro‐
glia‐mediated oxidative stress [120]. Another anti‐diabetic agent, GLP‐1 (glucagon‐like
peptide), is a hormone which maintains homeostasis between insulin and glucose. Exena‐
tide is a synthetic agonist for the GLP‐1 receptor and shows significant promise as neuropro‐
tective in PD animal models [123]. These studies describe the potent impact of insulin or anti‐
diabetic treatments as possible anti‐inflammatory neuroprotective therapies for PD.
7.2.5. Use of β‐adrenergic receptor agonists as an anti‐inflammatory agent in the treatment of PD
Beta2‐adrenergic receptors (β2AR) are seven transmembrane G‐protein‐coupled receptors
found on numerous cell types, including inflammatory cells and neurons. β2AR agonists are
FDA approved for the treatment of chronic obstructive pulmonary disorders (COPD), and
their use as treatment for neurodegenerative diseases such as PD represents a new and
potentially very productive therapeutic approach. In the CNS, microglia expresses high levels
of β2AR, and it has been demonstrated that long‐acting β2AR agonists such as salmeterol
(Advair, GlaxoSK) protect against DA neuronal death from microglia‐mediated neuroinflam‐
mation [16]. In addition to inhibiting the production of inflammatory mediators and oxida‐
tive stress responses by microglial cells, several in vivo studies also reported neuroprotective
roles of long‐acting β2AR agonists by inducing neurotrophic growth factors and astrocyte
activation [124, 125]. Long‐acting agonist such as salmeterol showed neuroprotective effects
by pretreatment in LPS‐stimulated long‐term mouse model and also by the treatment with
salmeterol after MPTP injection. Low dose of salmeterol treatment in these models sup‐
pressed the NF‐kB activation and its nuclear translocation. Similarly, it also reduces phos‐
phorylation of MAPK such as ERK1/2, p38, and JNK [126]. Furthermore, it has been shown
that low dose of salmeterol also inhibits TGF‐beta‐activated kinase 1 (TAK1), which is a
common upstream regulatory molecule for MAPK and NF‐kB activation, and involves in
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various inflammatory signaling pathways [127]. This suggests the anti‐inflammatory effects
of salmeterol by reducing phosphorylation of MAPK and NF‐kB activation via inhibition of
TAK1. The activation of β2AR stimulates MAPK signaling also via β‐arrestin‐dependent and
G‐protein‐independent mechanism [126]. Overall, these agonists can inhibit inflammatory
response and have potential to regulate inflammation in chronic inflammatory disorders of
CNS. These results suggest that β2AR agonists can be developed as anti‐inflammatory therapy
to subside the progressive loss of dopaminergic neurons in PD patients.
7.2.6. Use of morphinan‐related anti‐inflammatory compounds in PD
Several morphinan analogs such as naloxone, dextromethorphan, or naltrexone have been
described as anti‐inflammatory and neuroprotective. Morphine isomers (L‐morphine and its
D stereoenantiomer) can inhibit microglial activation and LPS‐ or MPP+‐induced neurotoxic‐
ity in rat primary mesencephalic cultures. Furthermore, it also suggests that morphinan
compounds bind to the catalytic subunit of PHOX and inhibits its activity leading to the
reduced production of superoxide and other pro‐inflammatory cytokines [128]. Similar results
were observed with sinomenine, a dextrorotatory isomer of morphine and protective effects
of sinomenine mediated through the inhibition of microglial PHOX activity [129]. Similarly,
3‐hydroxymorphinan (3‐HM), a metabolite of dextromethorphan, recently emerged as a potent
therapeutic agent for the treatment of PD. These compounds show neuroprotection by two
different pathways; one through a neurotrophic effect mediated by astrocytes and another by
their anti‐inflammatory effect mediated by the suppression of microglial activation. When
the 3‐HM compound was studied for its mechanistic effects in vivo, it was found that it
attenuated the depletion of striatal levels of dopamine and showed neuroprotection against
LPS‐ and MPTP‐elicited neurotoxicity [130]. These effects were observed even when drug was
administered post MPTP injections [131]. Collectively, these findings offer a different yet
highly potent new therapeutic direction for the treatment of neuroinflammation in PD.
7.2.7. Pro‐inflammatory transcription factor, NF‐kB as a therapeutic target in PD
Nuclear transcription factor NF‐kB plays an important role in inflammation. It regulates the
expression of various genes involved in immune function and cell survival. NF‐kB activa‐
tion has been reported in Substantia nigra of PD patients and in animal models of PD. The
inhibition of NF‐kB activation can suppress oxidative stress and production of pro‐inflamma‐
tory cytokines and chemokines in microglia [132]. Ghosh et al. [133] reported that intraperi‐
toneal injection of NBD (NF‐kB essential modifier‐binding domain) peptide reduces nigral
activation of NF‐kB, inhibits microglial activation in Substantia nigra, and improves motor
function in MPTP mouse model of PD. Selective inhibitors against IKK‐β also reduce micro‐
glial n and neuronal death in SNpc in MPTP‐intoxicated PD mice [133] and in LPS‐induced
neurodegeneration by inhibiting NF‐kB activation and decreasing the production of pro‐
inflammatory cytokines. It also suppresses the activity of microglial NADPH oxidase and
reduces the production of ROS [134]. These reports suggest the suppression of NF‐kB signaling
pathway in microglia is neuroprotective and represent NF‐kB as a strong potential target for
anti‐inflammatory therapy in the treatment of PD.
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7.2.8. Antioxidants as neuroprotective agents in PD
Oxidative stress and generation of free radicals have been reported to be a major effector of
neuronal death seen in neurodegeneration in PD. This can also be linked to other processes
such as nitric oxide toxicity, excitotoxicity, mitochondrial dysfunction, and inflammation.
Oxidative stress impairs cell viability by damaging lipid, proteins, and nucleic acids [135]. The
development of therapies against oxidative stress and free radicals may be beneficial in PD by
inhibiting the onset of apoptotic cell death and degeneration of nigrostriatal dopaminergic
neurons. The neurotoxin MPTP inhibits the mitochondrial electron transport chain and
suppresses the activity of mitochondrial complex I and eventually elevates oxidative stress
within DA neurons. MPTP also increases the production of free radicals and ROS by micro‐
glial cells, ultimately leading to the death of dopamine producing neurons. It has been found
that mice lacking the NADPH oxidase complex do not exhibit DA neurotoxicity from MPTP‐
or LPS‐induced neurodegeneration, and that the administration of NADPH oxidase inhibi‐
tor DPI can prevent DA neurotoxicity [136, 137]. Several other antioxidants have been
investigated in the treatment of PD, and it has been found that coenzyme Q10 is a potent
antioxidant and electron acceptor for mitochondrial complex I and II, can enhance activity of
complex I, and reduce oxidative stress [138]. Clinical trial with randomized, parallel group,
placebo controls, and double‐blind with multiple doses of CoQ10 (300, 600, or 1200 mg/day)
in 80 early PD patients showed that CoQ10 is well tolerated at doses up to 1200 mg/day, less
disability was developed in PD subjects, and symptomatic relief was higher in subjects
receiving the highest dose [139]. In contrast, a recent phase III, randomized, double‐blind,
placebo‐controlled clinical trial concluded that CoQ10 is safe and well tolerated but showed
no evidence of clinical benefits [140]. Another antioxidant and a pro‐drug of amino acid
cysteine called N‐acetyl‐cysteine (NAC) also showed neuroprotective effects. Preclinical data
suggest NAC is neuroprotective and can reduce oxidative stress and ROS accumulation.
Recently, a clinical trial with NAC intravenous infusion concludes that NAC enhances the level
of glutathione (a potent antioxidant) in blood and brain in PD patients [141]. Similarly,
Edaravone (MCI‐186, 3‐methyl‐1‐phenyl‐2‐pyrozolin‐5‐one) is a neuroprotective antioxidant,
generally prescribed for recovery of acute brain ischemia and cerebral infraction [142]. It
showed neuroprotective effects in MPP‐induced PC12 cells by reducing oxidative stress and
enhancing expression heme oxygenase‐1 expression (a cellular stress response protein) [143],
but clinical trials are yet to be done.
8. Conclusion
Inflammation plays an important role in the etiology of a number of different forms of PD, and
anti‐inflammatory drugs hold much promise as a therapeutic treatment for patients with mild
and moderate forms of PD. The continued evaluation of these drugs, including their efficacy,
target, and mechanism of action, hold much promise for the future treatment of PD.
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